PTEN and neoplasm: Pre-clinical studies [15] and clinical evidence from the analysis of a patient with advanced endometrial cancer [35] suggests that tumours with loss of PTEN expression, a recurrent aberration in OCCC [6, 7], may be sensitive to PARP inhibitors.